Top Page
Recordati Industria Chimica e Farmaceutica SPA
(LSE:REC)
Recordati Industria Chimica e Farmaceutica SPA (REC) vs. iShares MSCI Italy ETF (EWI)
Recordati Industria Chimica e Farmaceutica SPA Business Overview & Revenue Model
Recordati Industria Chimica e Farmaceutica SPA Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.48B | 2.34B | 2.08B | 1.85B | 1.58B | 1.45B |
| Gross Profit | 1.68B | 1.60B | 1.42B | 1.29B | 1.15B | 1.04B |
| EBITDA | 818.90M | 795.37M | 708.16M | 559.35M | 578.35M | 566.83M |
| Net Income | 407.26M | 416.51M | 389.21M | 312.34M | 385.97M | 354.98M |
Balance Sheet | ||||||
| Total Assets | 5.18B | 5.13B | 4.21B | 4.00B | 2.82B | 2.71B |
| Cash, Cash Equivalents and Short-Term Investments | 341.55M | 322.42M | 221.81M | 284.73M | 244.58M | 188.23M |
| Total Debt | 80.88M | 2.49B | 1.81B | 1.72B | 992.19M | 1.06B |
| Total Liabilities | 3.31B | 3.26B | 2.52B | 2.45B | 1.43B | 1.44B |
| Stockholders Equity | 1.87B | 1.88B | 1.69B | 1.55B | 1.38B | 1.28B |
Cash Flow | ||||||
| Free Cash Flow | 500.19M | 535.10M | 102.06M | 365.35M | 404.29M | 271.90M |
| Operating Cash Flow | 574.93M | 569.92M | 485.32M | 461.69M | 491.65M | 403.57M |
| Investing Cash Flow | -868.25M | -844.94M | -379.62M | -767.12M | -87.50M | -131.56M |
| Financing Cash Flow | 443.15M | 372.11M | -168.91M | 341.28M | -355.94M | -264.29M |
Recordati Industria Chimica e Farmaceutica SPA Technical Analysis
Recordati Industria Chimica e Farmaceutica SPA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €10.88B | 26.47 | 22.16% | 2.40% | 11.51% | 5.23% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
| ― | €4.95B | 24.36 | 12.16% | ― | ― | ― | |
73 Outperform | €465.17M | 28.10 | 2.06% | 17.78% | 63.72% | ||
| ― | €684.28M | 20.02 | 39.51% | ― | ― | ― | |
| ― | €431.84M | 19.21 | 6.75% | ― | ― | ― | |
| ― | €43.81M | 7.76 | ― | ― | ― |
Recordati Industria Chimica e Farmaceutica SPA Corporate Events
Recordati S.p.A. has provided an update on its share buyback program, initiated on April 30, 2025, to support stock options and performance share plans for its management. The company reported purchasing 114,072 ordinary shares between August 4 and August 8, 2025, at a weighted average price of 50.3567 Euros per share, holding 1.951% of its share capital as of August 8, 2025. This move is part of Recordati’s strategic efforts to enhance shareholder value and align management incentives with company performance.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its share buyback program, initially communicated in April 2025, with recent transactions executed by UBS Europe SE. From July 28 to August 1, 2025, the company purchased a total of 176,283 shares at a weighted average price of 51.7557 Euros per share. As of August 1, 2025, Recordati holds 3,965,975 own shares, representing 1.896% of its share capital. This buyback is part of Recordati’s strategy to allocate shares for stock option and performance share plans aimed at management incentives.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced the resignation of Dr. Livia Amidani Aliberti as Actual Auditor, effective immediately, due to personal reasons. Dr. Silvia Mina, previously an Alternate Auditor, will assume the role of Actual Auditor until the next Shareholders’ Meeting. This change is in accordance with the company’s Articles of Association and does not impact the company’s shareholding structure as neither auditor holds shares in the company.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has published its half-year financial report as of June 30, 2025, which has been approved by the Board of Directors and is now accessible to the public. This announcement underscores Recordati’s commitment to transparency and its strategic positioning in the pharmaceutical industry, potentially impacting stakeholders by providing insights into the company’s financial health and operational progress.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the execution of its share buyback program, initiated to support stock option and performance share plans for its management. The company purchased a total of 52,802 ordinary shares between July 21 and July 25, 2025, with an average price of €52.5805 per share. As of July 25, 2025, Recordati holds 3,815,712 own shares, representing 1.825% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati reported strong financial performance in the first half of 2025, with consolidated net revenues increasing by 11.7% to €1,323.8 million. The company signed a license and supply agreement with Amarin for the commercialization of Vazkepa® in Europe, enhancing its cardiovascular portfolio. Despite adverse exchange rate impacts, Recordati maintained its financial targets for 2025, demonstrating robust execution and strategic growth in both its Specialty & Primary Care and Rare Diseases sectors.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced an update on its share buyback program, which began on 30 April 2025. The program aims to purchase shares to support stock options and performance share plans for the management of the Recordati Group. From 14 to 18 July 2025, Recordati purchased 130,231 ordinary shares at an average price of €52.9464 per share. As of 18 July 2025, the company held 3,764,910 own shares, representing 1.800% of its share capital. This move is part of Recordati’s strategy to enhance shareholder value and support its incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program, which began on April 30, 2025, following the Shareholders’ Meeting resolution. The program aims to purchase shares to support stock options and performance shares plans for the company’s management. Between July 7 and July 11, 2025, Recordati purchased 75,466 shares at an average price of 53.8449 Euros per share, bringing its total holdings to 3,674,679 shares, representing 1.757% of its share capital. This move is part of Recordati’s broader strategy to enhance its market position and incentivize its management team, potentially impacting shareholder value and market perception.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced an update on its share buyback program, which was initiated to support stock options and performance share plans for the company’s management. From June 30 to July 4, 2025, the company purchased 80,423 ordinary shares at an average price of €53.5657, increasing its total holdings to 3,623,213 shares, representing 1.733% of its share capital. This strategic move aims to strengthen the company’s market position and provide incentives for its management team.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has engaged in transactions involving the sale and purchase of treasury shares. These transactions include the sale of shares to beneficiaries of stock option plans and the purchase of shares through a buy-back program executed by UBS Europe SE. This strategic move is likely aimed at optimizing capital structure and enhancing shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the execution of its share buyback program, which was initiated to support stock options and performance share plans for the company’s management. The company purchased a total of 90,057 ordinary shares between June 23 and June 27, 2025, increasing its total holdings to 3,563,650 shares, representing 1.704% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated the market on its ongoing share buyback program, initiated to support its stock options and performance share plans. The company purchased 89,172 ordinary shares between June 16 and June 20, 2025, reflecting a strategic move to enhance shareholder value and support future incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the progress of its share buyback program, which was initiated to support stock options and performance share plans for its management. Between June 9 and June 13, 2025, Recordati purchased 82,346 of its own shares, representing 1.620% of its share capital, as part of its strategy to enhance shareholder value and incentivize management.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati announced an update on its share buyback program, which began on April 30, 2025, following a resolution by the Shareholders’ Meeting. The program is intended to purchase shares for stock option and performance share plans for the company’s management. During the period from June 2 to June 6, 2025, Recordati purchased 70,709 ordinary shares, bringing its total holdings to 3,360,825 shares, representing 1.607% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated on its share buyback program initiated in April 2025, aimed at acquiring shares for stock option and performance share plans for management. Between May 26 and May 30, 2025, Recordati purchased 76,378 shares, holding 1.604% of its share capital by the end of May, reflecting its strategic focus on incentivizing management and aligning with shareholder interests.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR55.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program initiated on April 30, 2025. The company purchased 89,225 shares between May 19 and May 23, 2025, at an average price of 51.3752 Euros per share. This buyback is part of Recordati’s strategy to allocate shares for stock option and performance share plans for its management, reflecting its commitment to incentivizing its leadership and enhancing shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the progress of its share buyback program, initiated on April 30, 2025. The program, which aims to purchase shares for stock option and performance share plans, saw the acquisition of 88,677 ordinary shares between May 12 and May 16, 2025, reflecting the company’s strategic focus on incentivizing management and aligning with future incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.